

Pulmonary Function Testing Part II

Arthur Jones, EdD, RRT

Specialized testing regimens

- ^ **Bronchodilator benefit**
- ^ **Bronchial challenge testing**
- ^ **Exhaled nitric oxide analysis**
- ^ **Preoperative testing**
- ^ **Testing for disability**

Learning Objectives:

- ^ **Describe the purposes, physiologic bases devices and methods for diffusing capacity testing.**
- ^ **Describe the purposes, physiologic bases devices and methods for specialized testing regimens.**
- ^ **Describe the purposes, physiologic bases devices and methods for cardiopulmonary exercise testing.**

Diffusing Capacity Testing

Learning Objectives:

- ^ **Describe the purposes, physiologic bases devices and methods for metabolic testing.**
- ^ **Interpret results from diffusing capacity tests, specialized testing regimens, cardiopulmonary exercise tests and metabolic tests.**

Diffusing capacity

- ^ **Measures the rate of diffusion of gas across alveolar-capillary membrane**
- ^ **Measured as mL (gas) /min/mm Hg (pressure gradient)**

Anatomic diffusion pathway

- ^ Alveolar air
- ^ Alveolar wall
 - ◆ Surfactant layer
 - ◆ Alveolar epithelium
 - ◆ Alveolar basement membrane
- ^ Interstitial space

Physical laws governing diffusion

- ^ Henry's law- amount of gas dissolving in a liquid is proportional to the partial pressure of the gas ==> derives the solubility coefficient (Ks) of the gas.


Anatomic diffusion pathway

- ^ Capillary wall
 - ◆ Capillary basement membrane
 - ◆ Capillary endothelium
- ^ Plasma
- ^ RBC
 - ◆ Erythrocyte membrane
 - ◆ Intracellular erythrocyte fluid
- ^ Hemoglobin

Physical laws governing diffusion

- ^ Graham's law - rate of diffusion through a liquid is:
 - ◆ directly proportional to its Ks
 - ◆ inversely proportional to its GMW ==> CO2 diffuses 20X the rate of O2
 - ◆ high solubility of CO2 ==> diffusion defects will not affect CO2 exchange

Anatomic diffusion pathway



Physical laws governing diffusion

- ^ Fick's law - gas diffusion is:
 - ◆ directly proportional to:
 - alveolar surface area
 - pressure gradient
 - ◆ inversely proportional to:
 - alveolar thickness
 - gram molecular weight of gas

Diffusion limitations of gases

- △ O₂ can be diffusion and/or perfusion limited
- △ CO is diffusion limited, only ==> ideal gas to measure diffusing capacity
- △ Lung diffusing capacity is measured as DL_{CO} - diffusion in lung of carbon monoxide

Diffusion tests

- △ DL_{CO}ib (intrabreath) - analysis during a single exhalation
 - ◆ advantages
 - ▶ does not require breath hold
 - ▶ can be used during exercise
 - ◆ disadvantage
 - ▶ sensitive to V/Q mismatch
 - ▶ complex calculations

Diffusion tests

- △ DL_{CO}sb (single breath) - most common method
 - ◆ advantages
 - ▶ simple technique
 - ▶ rapid analysis
 - ◆ disadvantages
 - ▶ sensitive to V/Q mismatching
 - ▶ patient must be capable of breath holding for 10 sec.

DL_{CO} testing indications

- △ evaluation and follow up of parenchymal lung diseases
- △ evaluation and follow-up of emphysema and cystic fibrosis
- △ evaluation of cardiovascular diseases
- evaluation of pulmonary involvement in systemic inflammatory and collagen vascular diseases

Diffusion tests

- △ DL_{CO}rb (rebreathing)
 - ◆ advantages
 - ▶ most accurate method
 - ▶ least sensitive to V/Q mismatching
 - ▶ can be used during exercise
 - ◆ disadvantage
 - ▶ requires rapid analyzers
 - ▶ complex calculations

DL_{CO} testing indications

- △ evaluation of the effects of chemotherapy agents or other drugs; e.g., amiodarone
- △ evaluation of pulmonary hemorrhage
- △ evaluation for pneumonectomy or lung reduction surgery
- △ evaluation for disability

Contraindications for diffusion tests

- ^ CO toxicity
- ^ Severe hypoxemia (O2 removed during test)
- ^ Inability to cooperate; e.g., breath holding
- ^ Large meal or vigorous exercise immediately before the test
- ^ Smoking within 24 hours of test

DLCOSb procedure

^ Calculation

- ◆ VA - alveolar volume
- ◆ 60 - correction from sec. to min.
- ◆ PB - barometric pressure
- ◆ T - breath hold time (sec)
- ◆ Ln - natural logarithm
- ◆ FCOI - initial fraction of CO
- ◆ FCOF - final fraction of CO

$$DLCOSb = \frac{VA (STPD) \times 60}{(PB - PH_2O) (T)} \times \ln \frac{FCOI}{FCOF}$$

DLCOSb equipment

- ^ spirometer
- ^ automatic valve - for gas delivery, breath holding and sampling
- ^ end-tidal sampler
- ^ gas analyzers - CO and He
- ^ gas mixture:
 - ◆ 0.3% CO
 - ◆ 10% He
 - ◆ 21% O2
 - ◆ balance N2

DLCOSb acceptability criteria

- ^ Test volume must be >90% previously measured VC
- ^ End-inspiratory breath hold must be 9-11 sec
- ^ Expiration to RV \leq 4 sec
- ^ VD must clear before alveolar sampling
- ^ Reproducibility criteria- two tests within 10% or 3.0 ml CO/min/mmHg
- ^ Report- mean value of two tests

DLCOSb procedure

- ^ patient performs FVC maneuver
- ^ inspires to TLC
- ^ holds breath for 9 - 11 sec.
- ^ exhales
- ^ alveolar sample collected between 750 - 1000 mL

DLCO predicted value

- ^ Normal DLCO = 25 ml/min/mmHg \pm 20%
- ^ Predicted based on:
 - ◆ BSA
 - ◆ Hb - 1 mg/dL ==> 7% change in DLCO
 - ◆ Age - inverse relationship
- ^ Interpretation must consider lung volume

Factors affecting DL_{CO}

- ^ Alveolar surface area
- ^ V/Q abnormalities
- ^ Parenchymal thickening, e.g. fibrosis
- ^ Edema
- ^ Consolidation
- ^ Pulmonary capillary pressure
- ^ RBC, Hb quantities
- ^ Pulmonary capillary quantity

Prognostic value of DL_{CO}

- ^ Determines when COPD develops into emphysema
- ^ Predicts complications after surgical resection of lung
- ^ Predicts mortality in pulmonary arterial hypertension

Conditions with increased DL_{CO}

- ^ Obesity
- ^ Asthma
- ^ Left-to-right shunt
- ^ CHF (without edema)
- ^ Early polycythemia
- ^ Large lung volume
- ^ Exercise
- ^ Supine position

Bronchodilator Benefit & Bronchial Challenge Testing

Conditions with decreased DL_{CO}

- ^ Decreased surface area
 - ◆ emphysema
 - ◆ lung resection
- ^ Increased wall thickness
 - ◆ hypersensitivity pneumonitis
 - ◆ fibrosis
 - ◆ sarcoidosis
- ^ Decreased carrying capacity - anemia

Bronchodilator benefit testing

- ^ Purpose- determine value of bronchodilators in patient management
- ^ Indications
 - ◆ clinical evidence of reactive airways
 - ◆ wheezing
 - ◆ dyspnea
 - ◆ FEV₁% <70%

Bronchodilator benefit testing

- △ **Preconditions for testing**
 - ◆ No short-acting beta agonists or anticholinergics for 4 H
 - ◆ No long-acting beta agonists for 12 H
 - ◆ No long-acting anticholinergic for 24 H
 - ◆ No cromlyn, nedocromil for 24 H
 - ◆ No leukotriene modifiers for 24 H
 - ◆ Maintain inhaled steroids

Bronchodilator benefit testing

- △ **Medication administration**
 - ◆ beta agonist - 1 pf Q30s x 4
 - ◆ ipratropium - 1 pf Q30s x 4
- △ **Interval before post-testing**
 - ◆ beta agonist - 10-15 min.
 - ◆ ipratropium - 30 min.

Bronchodilator benefit testing

- △ **Laboratory requirements**
 - ◆ Cooperative patient
 - ◆ Skilled technologist
 - ◆ Maintained & calibrated equipment
 - ◆ ACLS capabilities
 - ◆ Patient care capabilities in institution

Bronchodilator benefit testing

- △ **Significant improvements**
 - ◆ > 12% and 200 mL increase in FEV₁ or FVC
 - ◆ >30% increase in sGaw

Bronchodilator benefit testing

- △ **Pretests - may include:**
 - ◆ spirometry; e.g., FEV₁
 - ◆ sGaw measurement
 - ◆ lung volumes
 - ◆ diffusing capacity

Bronchodilator benefit testing

- △ **Insignificant improvement**
 - ◆ may test after time using a medication
 - ◆ may test with a different medication
 - ◆ check for symptomatic improvement
- △ **Decreased posttest parameters**
 - ◆ paradoxical drug response
 - ◆ fatigue

Bronchodilator benefit testing

^ Calculating % change

$$\%FEV_1 \text{ change} = \frac{\text{Post } FEV_1 - \text{Pre } FEV_1}{\text{Pre } FEV_1} \times 100$$

Example: Pre = 1.2L; Post = 1.7L

$$\%FEV_1 \text{ change} = \frac{1.7L - 1.2L}{1.2L} \times 100 = 42\%$$

Bronchial challenge testing

^ Contraindications

- ◆ symptoms; e.g., wheeze, cough
- ◆ ventilatory impairment
- ◆ recent cardiac event or stroke
- ◆ cerebral aneurysm
- ◆ uncontrolled hypertension
- ◆ current use of anticholinesterase agent
- ◆ pregnancy, lactation

Bronchial challenge testing

^ Purposes

- ◆ detect airway hyperreactivity
- ◆ isolate cause of hyperreactivity
- ◆ quantify severity of bronchospasm
- ◆ assess changes in bronchoreactivity

Bronchial challenge testing

^ Provocative agents

- ◆ Methacholine - parasympathetic stimulator
 - most common
 - prepared by pharmacy
- ◆ Histamine - mechanism of action uncertain
- ◆ Exercise - exercise-induced bronchospasm (EIB)

Bronchial challenge testing

^ Indications

- ◆ exclude a diagnosis of airway hyperreactivity
- ◆ evaluate occupational asthma
- ◆ assess the severity of bronchospasm
- ◆ determine the relative risk of developing asthma
- ◆ assess response to therapeutic interventions

Bronchial challenge testing

^ Side effects

- ◆ Methacholine
 - headache
 - itching
 - signs and symptoms of severe allergic reaction
- ◆ Histamine
 - same as for methacholine
 - flushing

Bronchial challenge testing

^Preconditions

- ◆ No bronchodilators, as for bronchodilator benefit test
- ◆ No systemic steroids for 12 hours
- ◆ No cromolyn for 48 hours
- ◆ No antihistamines for 48 hours
- ◆ No exercise, cold air for 2 hours
- ◆ No smoking for 6 hours
- ◆ No caffeine for 6 hours
- ◆ No beta-blocking agents

Methacholine challenge testing

^Procedure

- ◆ Baseline mechanics - FVC, FEV₁, sGaw, etc.
- ◆ Inhaled NSS (control dose)
- ◆ Wait 3 minutes
- ◆ Repeat measure
- ◆ FEV₁ ≤ 80% (of pretest) ==> reactivity ==> stop test
- ◆ FEV₁ ≥ 80% (of pretest) ==> non-reactivity ==> proceed

Methacholine challenge testing

^Procedure

- ◆ 5 breath dosimeter
 - ▶ standardizes dose by volume
 - ▶ most precise
 - ▶ requires dosimeter
- ◆ 2 minute tidal breathing
 - ▶ standardizes dose by time
 - ▶ requires only small volume nebulizer


Methacholine challenge testing

^Procedure - 5 breath dosimeter

- ◆ 5 breaths methacholine - 0.0625 to 16 mg/mL
- ◆ wait 3 minutes
- ◆ repeat, until:
 - ▶ FEV₁ ≤ 80% control
 - ▶ methacholine concentration = 16 mg/mL

Methacholine challenge testing

^5 breath dosimeter



Methacholine challenge testing

^Procedure - 2 min. tidal breathing

- ◆ administer NSS control dose
- ◆ posttest, as for dosimeter
- ◆ administer methacholine in five, quadrupled doses or ten doubled doses from 0.0625 - 16 mg/mL
- ◆ wait 3 minutes between,
- ◆ repeat, until:
 - ▶ FEV₁ ≤ 80% control
 - ▶ methacholine concentration = 16 mg/mL

Methacholine challenge testing

^ Evaluation of results

- ◆ provocative dose (PC20)
 - ▶ where FEV_1 decreased by 20%
 - ▶ calculated using last and next-to-last dosages
- ◆ sGAW decrease of 35% ==> positive response

Exercise challenge testing

^ Preconditions

- ◆ withhold activity and medications, as for methacholine challenge
- ◆ pretest ECG
- ◆ pretest $FEV_1 \geq 65\%$ predicted
- ◆ room temperature $< 25\text{ C}^\circ$
- ◆ relative humidity $\leq 50\%$

Histamine challenge testing

- ^ Preconditions similar to methacholine challenge, with addition of abstention from antihistamines and H1 receptor antagonists (48 H)
- ^ Procedure similar to methacholine, with ascending, double-dosing from .03 to 10 mg/mL

Exercise challenge testing

^ Procedure

- ◆ baseline mechanics
- ◆ nose clips to remove nasal conditioning
- ◆ continuous ECG and BP
- ◆ exercise on treadmill or bicycle ergometer

Exercise challenge testing

- ^ Purpose - to diagnose exercise induced bronchospasm (EIB)
- ^ Indicated for patients with normal resting PFTs who report dyspnea on exertion

Exercise challenge testing

^ Procedure

- ◆ low level exercise for 1-2 min.
- ◆ vigorous exercise
 - ▶ 85% HRmax - maximum heart rate = (220 - age)
 - ▶ 6-8 minutes
- ◆ posttest mechanics

Exercise challenge testing


^ Evaluation of results

- ◆ greatest response usually 5-10 min. after exercise - may be severe
- ◆ key value = % decrease in mechanics produced by exercise
- ◆ EIB signified by decrease >10%
- ◆ normal response is for FEV₁ and sGAW to increase (improve)

Nitric oxide (NO) physiology

^ Louis Ignarro, MD, PhD

- ◆ Nobel Prize winner, 1998
- ◆ Research on NO



Exhaled Nitric Oxide Analysis

Nitric oxide (NO) physiology

^ NO synthesis catalyzed by NO synthases

- ◆ endothelial
- ◆ neural
- ◆ induced - by inflammatory cytokines; e.g., as in asthma

Nitric oxide (NO) physiology

^ NO - multipurpose molecule that mediates many physiologic processes, including:

- ◆ smooth muscle relaxation
- ◆ platelet inhibition
- ◆ neurotransmission
- ◆ apoptosis (programmed cell death)
- ◆ immune regulation

Nitric oxide (NO) physiology

^ eNO is noninvasive marker for airway inflammation, that:

- ◆ increases in patients with atopic (allergic) asthma
- ◆ decreases in asthmatic subjects treated with inhaled corticosteroids
- ◆ correlates with the sputum eosinophil quantity

Diagnostic utility of eNO

- △ FENO for lung transplant patient may detect infection, rejection and bronchiolitis obliterans
- △ FENO reflects degree of asthma control by steroids
- △ Asthma diagnosis based on FENO is less expensive than standard methods

FENO analysis

- △ Off-line sampling
 - ◆ patient inhales to TLC from NO scrubber or reservoir of NO-free gas
 - ◆ exhales VC with 5 cm H₂O resistance @ 0.35 L/sec
 - ◆ sample collected in mylar balloon
 - ◆ analysis within 12 H

Diagnostic utility of eNO

- △ Smoking does NOT devalue FENO in asthma control
- △ FENO analysis is NOT validated for acute exacerbations
- △ FENO reflects inflammation, NOT bronchospasm

FENO analysis

- △ Online sampling
 - ◆ patient inhales to TLC through scrubber
 - ◆ patient exhales VC into analyzer at controlled resistance

FENO analysis

- △ Chemiluminescent analyzer
- △ FENO reported in parts per billion (ppb) @ L/sec
- △ Measurement techniques:
 - ◆ off-line - sample collected in device for later analysis
 - ◆ online - sample collected at the mouth
 - ◆ nasal sampling

NIOX MINO™ FENO analyzer



Image courtesy of Aerocrine

FENO analysis



Bedmont FeNO analyzer



Solgroup Geanox FeNO analyzer

Preoperative testing:

- ▲ Purposes - for abdominal, chest procedures, to:
 - ◆ assess risk (operability?)
 - ◆ predict postoperative function
 - ◆ plan postoperative patient care

FENO interpretation

- ▲ Normal values
 - ◆ adults ≤ 35 ppb
 - ◆ children ≤ 25 ppb
- ▲ Elevated levels reflect eosinophilic inflammation
- ▲ Downward trends reflect effects of steroid therapy
- ▲ COPD does NOT elevate FENO

Preoperative testing:

- ▲ Postoperative function may improve in some lung resection cases
- ▲ Function testing does not predict postoperative quality-of-life

Preoperative Testing

Preoperative testing:

- ▲ Indications
 - ◆ history of smoking (>20 pk/yrs.)
 - ◆ active pulmonary symptoms
 - ◆ abnormal physical examination
- ▲ Conditional indications
 - ◆ evidence of pulmonary infection
 - ◆ morbid obesity
 - ◆ debilitation, malnourishment
 - ◆ age > 70 yrs.

Preoperative tests:

- ▲ Lung volumes, including VTG for pulmonary resection for emphysema
- ▲ Spirometry with maximal bronchodilation
- ▲ Perfusion, V/Q scans, contrast MRI - can be used to estimate post-operative FEV₁ for lung resections
- ▲ Measurement of FEV₁ on first day post-op is good predictor of morbidity

Interpretation guidelines

Test	Increased risk	Significant risk
FVC	<50% pred	<1.5 L
FEV1	<2.0 L or <50% pred	<1.0 L
MVV	NA	<50% pred
PaCO ₂	NA	>45 mm Hg
DLCO	<60% pred	
VO ₂ _{MAX} (O ₂ uptake)	<20 mL/kg/min	<10 mL/kg/min

Preoperative tests:

- ▲ DLCO - lung resection
- ▲ arterial blood gases - patients with documented pulmonary disease
- ▲ bronchodilator benefit - patients with obstructive disease
- ▲ exercise stress testing
 - ◆ cardiac surgery
 - ◆ borderline predicted post-op lung function

Pause for a Cause

Interpretation guidelines

Test	Increased risk
FVC	<50% pred
FEV1	<2.0 L or <50% pred
MVV	NA
PaCO ₂	NA
DLCO	<60% pred
VO ₂ _{MAX} (O ₂ uptake)	<20 mL/kg/min

Testing for disability

- ▲ Disability - the inability to perform tasks required for employment, due to impairments:
 - ◆ mental
 - ◆ physical
 - ◆ political
 - ◆ religion


Testing for disability

- ▲ History
- ▲ Physical examination
- ▲ Imaging studies
- ▲ PFTs
 - ◆ spirometry
 - ◆ diffusing capacity
 - ◆ arterial blood gases
 - ◆ exercise testing

Disability evaluation

- ▲ Blood gases & impairment
 - ◆ PaO₂ < 55 mm Hg on 0.21 OR
 - ◆ PaO₂ < 60 mm Hg on 0.21 AND
 - ▶ pulmonary hypertension OR
 - ▶ cor pulmonale OR
 - ▶ erythrocytosis OR
 - ▶ hypoxemia worsened with mild exercise

Algorithm for disability



Disability evaluation

- ▲ Additional factors to consider
 - ◆ Subject cooperation (malingering)
 - ◆ Hx of emergency treatment for asthma
 - ◆ Failure to receive appropriate care
 - ◆ Deconditioning (couch potato)
 - ◆ Coexisting disorders
 - ◆ Impairment that is difficult to measure

Disability evaluation

- ▲ Obstruction (COPD) - FEV₁
- ▲ Restriction - FVC
- ▲ Asthma
 - ◆ FEV₁
 - ◆ episode frequency

**Cardiopulmonary
Exercise Testing (CPET)**

Indications for exercise testing:

- ▲ Diagnose cardiopulmonary disorders, often, to distinguish between cardiac, vs. pulmonary dx
- ▲ Measure impairment (disability)
- ▲ Evaluate therapy
- ▲ Develop exercise prescriptions (rehabilitation)
- ▲ Assess fitness for occupations, physical activities, etc.

Contraindications for exercise testing

- ▲ **Cardiovascular conditions:**
 - ◆ acute pericarditis
 - ◆ CHF
 - ◆ recent MI
 - ◆ heart block - 2nd or 3rd degree
 - ◆ tachydysrhythmias
 - ◆ uncontrolled hypertension
 - ◆ unstable angina
 - ◆ recent systemic or pulmonary embolus
 - ◆ aortic stenosis

Contraindications for exercise testing

- ▲ Limiting neurologic, neuromuscular or orthopedic conditions
- ▲ Pulmonary contraindications:
 - ◆ $FEV_1 < 30\%$
 - ◆ room air $PaO_2 < 40$ mm Hg
 - ◆ $PaCO_2 > 70$ mm Hg
 - ◆ severe pulmonary hypertension

Pulmonary changes with exercise

- ▲ TV increases early
- ▲ Respiratory rate increases late
- ▲ V_d/V_t decreases
- ▲ V/Q equalizes
- ▲ Capillary transit time decreases - increased velocity of blood

Contraindications for exercise testing

- ▲ **Cardiovascular conditions:**
 - ◆ acute pericarditis
 - ◆ CHF
 - ◆ recent MI
 - ◆ heart block - 2nd or 3rd degree

Cardiovascular changes with exercise

- ▲ **Cardiac output**
 - ◆ Stroke volume- increases to maximum value
 - ◆ HR_{MAX}
 - ▶ reached at exhaustion
 - ▶ $HR_{MAX} = 220 - \text{age}$

Cardiovascular changes with exercise

^ Blood pressure

- ◆ systolic increases
- ◆ diastolic remains stable
- ◆ pulse pressure increases

Metabolic changes with exercise

$$\text{^ METS} = \frac{\text{VO}_{2\text{MAX}}}{3.5 \text{ ml/min} \times \text{BW}}$$

$$\text{^ Normal METS (sedentary)} = 7$$

$$\text{^ Normal VO}_{2\text{MAX}} = (7 \times 3.5) = 24.5 \text{ ml/min/kg}$$

Cardiovascular changes with exercise

^ Blood pressure

- ◆ systolic increases
- ◆ diastolic remains stable
- ◆ pulse pressure increases

^ Distribution of circulation - increased perfusion of musculature & skin

^ O₂ pulse (mL O₂ per heart beat) - increases.

- ◆ O₂ pulse = VO₂/HR
- ◆ index of stroke volume

Metabolic changes with exercise

^ 1 MET -- rest

^ 4 METS -- housework, bowling

^ 6 METS -- farming, tennis

^ 8 METS -- heavy manual labor, skiing

^ 12 METS -- hockey

^ 18 METS -- rowing, swimming

Metabolic changes with exercise

^ O₂ consumption

- ◆ Normal VO₂ = 250 ml/min (3.5 ml/kg BW)
- ◆ VO_{2MAX} = greatest O₂ consumption a person can reach
- ◆ Normal VO_{2MAX} = 7 times resting value
- ◆ METS - unit relating VO_{2MAX} to resting value

Metabolic changes with exercise

^ CO₂ production increases proportional to VO₂, up to anaerobic threshold, then increases at faster rate to buffer lactic acid.

^ RQ (VCO₂/VO₂) - increases to 1.0, just before exhaustion

^ pH - becomes acid after anaerobic threshold is reached.

Exercise limits

- ^ **Anaerobic threshold (AT)**
 - ◆ Point at which anaerobic metabolism begins in response to exercise
 - ◆ Greatest work level, or O₂ consumption that can be produced before lactic acid is produced.
- ^ **Physical exhaustion normally occurs shortly after passing the AT.**

Testing for general fitness

- ^ **12 minute walking distance**
 - ◆ subject walks as far and fast as possible for 12 min.
 - ◆ distance walked reflects fitness

Causes of exhaustion

- ^ **Work to eliminate CO₂ becomes excessive - ventilation produces more CO₂ than excretion**
- ^ **Cardiovascular system cannot oxygenate tissues**
- ^ **Depletion of glycogen - energy need**
- ^ **Excessive perception of symptoms; e.g., dyspnea, dizziness, chest tightness**

Testing for general fitness

- ^ **Harvard step test**
 - subject steps up and down platform for five minutes
 - ◆ recovery heart rate measured 1 min after exercise - lower rate ==> greater fitness

Click for video on step test (4.5 min.)
http://www.youtube.com/watch?v=mekPTS_LVv4&feature=related

General types of tests

- ^ **Tests to evaluate fitness**
- ^ **Tests to evaluate effects of exercise on oxygenation**
- ^ **Tests to evaluate exercise tolerance (stress tests)**

Testing to evaluate desaturation

- ^ **Purposes:**
 - ◆ to detect diffusion defect
 - ◆ to evaluate effects of O₂ therapy on exercise tolerance
- ^ **If pre-exercise SaO₂ < 90, then supplemental O₂ is needed during test**

Testing to evaluate desaturation

- ^ Subject exercises on treadmill or ergometer for 6 min.
- ◆ Parameters monitored:
 - Pre-exercise SaO₂, SpO₂-correlate values
 - Exercise SpO₂
 - ECG
 - Blood pressure

Exercise testing equipment

- ^ Treadmill
 - ◆ Advantages
 - familiar exercise
 - typical activity (ADL)

Testing to evaluate desaturation

- ^ Results
 - ◆ Normally, SpO₂ increases, due to improved VQ matching
 - ◆ SpO₂ > 90% after 6 minutes ==> no desaturation
 - ◆ SpO₂ decreased by 5% or drops to less than 85%, test terminated and results are positive for desaturation and likely diffusion defect

Exercise testing equipment

- ^ Treadmill
 - ◆ Disadvantages
 - subject weight is a factor
 - large, heavy, noisy
 - expensive
 - safety issues

FYI - click to see treadmill misadventures (2 min)
<http://www.youtube.com/watch?v=u7SOOg-5LBg>

Types of exercise tolerance tests

- ^ Constant work
- ^ Incremental work- more common
 - ◆ staged increments - stepwise
 - ◆ ramp increments - constant

Exercise testing equipment

- ^ Bicycle ergometer
 - ◆ Advantages
 - workload unaffected by weight
 - workload precisely measured
 - small, portable
 - inexpensive
 - safer than treadmill

Exercise testing equipment

- ▲ Bicycle ergometer
 - ◆ Disadvantages
 - ▶ unfamiliar exercise
 - ▶ not ADL
 - ◆ yields results slightly different from treadmill

Exercise tolerance testing

- ▲ Preliminary assessment
 - ◆ Hx & Px
 - ◆ 12 lead ECG
 - ◆ PFTs
 - ▶ Spirometry
 - ▶ MVV
 - ▶ DLCO

Exercise testing equipment

- ▲ Gas volume measurement device
- ▲ Gas collection, mixing devices
- ▲ Gas analyzers - O₂, CO₂
- ▲ Pulse oximeter
- ▲ ECG monitor - filtered for motion artifact
- ▲ Blood pressure monitor
- ▲ Crash cart

Exercise tolerance testing

- ▲ Obtain resting values
 - ◆ arterial blood gas
 - ◆ lactate (in some labs)
 - ◆ SpO₂- correlate with SaO₂
 - ◆ TV, f, VE
 - ◆ PetCO₂, PetO₂
 - ◆ HR, BP, ECG pattern

Exercise tolerance testing

- ▲ Preparation of subject
 - ◆ comfortable clothes
 - ◆ no meal within 2 H
 - ◆ no smoking, coffee within 2 H
 - ◆ continue medications as prescribed
 - ◆ orient to equipment & procedures - include hand signals

Exercise tolerance testing

- ▲ Practice at minimal work- check monitors & equipment
- ▲ Exercise- increase workload
 - ◆ intervals
 - ◆ ramp
- ▲ Monitor continuously or sample at each work level- depends on system

Click for video of exercise testing (2 min.)

<https://www.youtube.com/watch?v=xx83GohD5u4&t=8s>

Exercise tolerance testing

^ Indicators to stop test:

- ◆ Exhaustion - desired endpoint
- ◆ CNS symptoms- vertigo, etc.
- ◆ Nausea, vomiting
- ◆ Chest pain, SOB
- ◆ SpO2 drop >5%
- ◆ Dysrhythmias- frequent PVCs, etc.
- ◆ PSYS > 250 mm Hg
- ◆ Equipment failure
- ◆ Death

Data reported

- ^ VE, TV, f
- ^ $VO_2 = (FIO_2 \times VI) - (FEO_2 \times VE)$
- ^ $METS = VO_{2MAX} / 3.5 \text{ ml /min} \times BW$
- ^ $CO_2 \text{ production} = (FECO_2 - FICO_2)VE$
- ^ $O_2 \text{ pulse} = VO_2 \times 1000/HR$
- ^ $Vd/Vt = (PaCO_2 - PetCO_2)/PaCO_2$
- ^ $R = VO_2/VCO_2$

Exercise tolerance testing

^ Posttest cool down period

- ◆ minimal exercise
- ◆ final measurements

Click to see cardiac stress testing (2.5 min.)
http://www.youtube.com/watch?v=x_Z0GF6AuTw

Normal responses

- ^ $VO_{2max} \geq 95\% \text{ pred}$
- ^ $VE_{max} \geq 70\% \text{ MVV}$
- ^ PaO2, SpO2 WNL
- ^ Vd/Vt values decreases
- ^ $HR_{max} \geq 90\% \text{ pred}$
- ^ O2 pulse increases

Indicators of maximal effort

- ^ $VO_{2max} \geq 85\% \text{ pred}$
- ^ $VE_{max} \geq 70\% \text{ MVV}$
- ^ $HR_{max} > 90\% \text{ pred}$
- ^ Blood lactate $\geq 4 \text{ mM/L}$

Interpretation of abnormal results

Parameters at Maximal Exercise	Poor Conditioning
VO2max	Low
METS	Low
VEmax/MVV	Low
SpO2 SaO2	Normal
Vd/Vt	Normal
HRmax/workload	High
O2 pulse	Normal

Interpretation of abnormal results

Parameters at Maximal Exercise	Poor Conditioning	Pulmonary disorders
VO ₂ max	Low	Low
METS	Low	Low
VE _{max} /MVV	Low	High (low MVV)
SpO ₂ SaO ₂	Normal	Low (if diffusion limited)
Vd/Vt	Normal	Normal- High (high if VDA)
HR _{max} /workload	High	Normal
O ₂ pulse	Normal	Normal

Purposes of metabolic testing:

- ▲ Measure nutritional requirements
- ▲ Measure relative metabolic contributions of:
 - ◆ carbohydrates
 - ◆ lipids
 - ◆ protein

Interpretation of abnormal results

Parameters at Maximal Exercise	Poor Conditioning	Pulmonary disorders	Cardiovascular disorders
VO ₂ max	Low	Low	Low
METS	Low	Low	Low
VE _{max} /MVV	Low	High	Low
SpO ₂ SaO ₂	Normal	Low	Normal
Vd/Vt	Normal	Normal- High	Normal
HR _{max} /workload	High	Normal	High
O ₂ pulse	Normal	Normal	Low

Rationale for bedside assessment

- ▲ Critically ill patients have highly variable metabolic needs
- ▲ Patients often are NPO and receive all nourishment via total parenteral nutrition (TPN)

Metabolic Testing

Specific indications for testing

- ▲ COPD
- ▲ Multiple trauma
- ▲ Acute pancreatitis
- ▲ Organ transplant patients
- ▲ Morbid obesity
- ▲ Hyper or hypo-metabolism
- ▲ Prolonged mechanical ventilation and NPO status (weaning)

Sources of nutritional depletion

- ^ Vomiting, NG suctioning
- ^ Diarrhea
- ^ Malabsorption
- ^ Elevated metabolism, due to:
 - ◆ fever
 - ◆ surgery
 - ◆ trauma

Calorimetry methods

- ^ Direct- complete enclosure of body & measurement of heat production
- ^ Indirect- uses VO_2 , VCO_2 , VE to calculate energy expenditure
 - ◆ Closed circuit method
 - ◆ Open circuit method

Complications of malnourishment

- ^ Impaired function of all organ systems
- ^ Immunocompromise
- ^ Delayed wound healing
- ^ Increased ventilatory load due to:
 - ◆ increased oxygen demand
 - ◆ increased CO_2 production

Closed circuit method

- ^ Subject rebreathes in closed system
- ^ CO_2 is absorbed
- ^ O_2 measured volumetrically with spirometer ==> $VI - VE = VO_2$
- ^ Not compatible with current ventilators

Methods for nutritional assessment

- ^ Anthropometric
 - ◆ skin fold thickness
 - ◆ arm circumference
- ^ Laboratory assessment - serum proteins
- ^ Calorimetry

Open circuit method

- ^ Hood or canopy for spontaneously breathing patients
- ^ Ventilator - attaches at airway
- ^ Measured parameters:
 - ◆ FIO_2 & FEO_2
 - ◆ $FICO_2$ & $FECO_2$
 - ◆ VE

Open circuit method

- ▲ Hood or canopy for spontaneously breathing patients



Significance of results

- ▲ $RQ < 0.67$ or $RQ > 1.3$ ==> error
- ▲ $RQ < 0.7$ ==> starvation or ketosis
- ▲ RQs for predominant substrate
 - ◆ carbohydrates = 1.0
 - ◆ lipids = 0.71
 - ◆ protein = 0.82
- ▲ $REE > \text{caloric intake}$ ==> underfeeding
- ▲ $REE < \text{caloric intake}$ ==> overfeeding

Test administration

- ▲ Patient preparation
 - ◆ Avoid stimulants prior to test
 - ◆ Fast for 2 - 4 H, if PO
 - ◆ Continuous feedings, if NPO
 - ◆ No ventilator adjustments immediately before testing (within 90 min)
- ▲ Neutral thermal environment must be maintained - no thermal stress
- ▲ Measurements made during steady state

Summary & Review

- ▲ Diffusing capacity
 - ◆ gas laws
 - ◆ pathophysiology
 - ◆ DLCOsb - most common
 - ◆ normal DLCOsb = 25 mL/min/mm Hg
 - ◆ increased with obesity, asthma
 - ◆ decreased with emphysema, fibrosis

Calculated parameters

- ▲ resting energy expenditure (REE)
 - ◆ VO_2
 - ◆ VCO_2
 - ◆ UN (urinary N₂) - not critical to test
- ▲ Caloric equivalents for:
 - ◆ carbohydrates
 - ◆ lipids
 - ◆ protein
- ▲ respiratory quotient (RQ)

Summary & Review

- ▲ Bronchodilator benefit - before and after bronchodilator tests
 - ◆ indications
 - ◆ preconditions
 - ◆ procedure
 - ◆ significant improvement -
 - ▶ 12% FEV_1 increase and 200 mL FEV_1 or FVC increase
 - ▶ 30% sGAW increase

Summary & Review

- ^ **Bronchial challenge testing - detects and measures airway reactivity**
 - ◆ provocative agents - methacholine, histamine or exercise
 - ◆ preconditions, procedure
 - ◆ significant results
 - ▶ PC20 - dose where FEV₁ decreased by 20%
 - ▶ decrease in mechanics produced by exercise

Summary & Review

- ^ **Testing for disability - to detect and measure physical impairment**
 - ◆ battery - Hx & Px, spirometry, DLCO, ABGs, CPET
 - ◆ obstruction - FEV₁
 - ◆ restriction - FVC
 - ◆ asthma - FEV₁, episodes
 - ◆ oxygenation - PaO₂, comorbidities; e.g., pulmonary hypertension

Summary & Review

- ^ **Exhaled nitric oxide (eNO) analysis**
 - ◆ production of NO increased by allergic asthma - noninvasive marker for inflammation
 - ◆ sampled on-line or off-line
 - ◆ normals = ≤ 35 ppb for adults and ≤ 25 ppb for children
 - ◆ increased ==> eosinophilic inflammation
 - ◆ decreased trend ==> effective steroid therapy

Summary & Review

- ^ **Cardiopulmonary exercise testing**
 - ◆ purposes:
 - ▶ diagnose cardiopulmonary disease
 - ▶ distinguish pulmonary vs. cardiac dx
 - ▶ assess fitness
 - ▶ develop exercise prescriptions
 - ◆ normal changes with exercise - cardiac pulmonary, metabolic
 - ◆ parameters - VO₂max, METS, O₂ pulse, HRmax

Summary & Review

- ^ **Preoperative testing - for risk, postoperative function and care planning**
 - ◆ Indications; e.g., smoking history
 - ◆ tests; e.g., spirometry, DLCO, ABGs imaging. CPET
 - ◆ increased risk; e.g., FVC ≤ 50% pred.
 - ◆ significant risk; e.g., FVC ≤ 1.5 L

Summary & Review

- ^ **Cardiopulmonary exercise testing**
 - ◆ types of tests - fitness, evaluation of oxygenation, stress tests
 - ◆ fitness - Harvard step, 12 min. walking
 - ◆ oxygenation - 6 min. exercise with continuous SpO₂

Summary & Review

- ^ **Cardiopulmonary exercise testing**
 - ◆ stress testing - treadmill or bicycle ergometer exercise to exhaustion
 - ◆ monitors:
 - expired O₂ and CO₂
 - SpO₂
 - TV, f, VE
 - HR, BP, ECG
 - lactate (optional)

Summary & Review

- ^ **Metabolic testing - to measure nutritional requirements and determine metabolic contributions**
 - ◆ indications; e.g., prolonged mechanical ventilation
 - ◆ calorimetry methods
 - direct vs. indirect
 - indirect - closed, vs. open circuits

Summary & Review

- ^ **Cardiopulmonary exercise testing**
 - ◆ indicators of maximal effort; e.g., HR_{max} > 90% pred.
 - ◆ normal responses - oxygenation stable or improved, O₂ pulse increases

Summary & Review

- ^ **Metabolic testing**
 - ◆ calorimeter attached to airway and measures:
 - FIO₂, FEO₂
 - FICO₂, FECO₂
 - VE
 - ◆ calculated values:
 - resting energy expenditure (REE)
 - caloric equivalents
 - respiratory quotient (RQ)

Summary & Review

- ^ **Cardiopulmonary exercise testing**
 - ◆ indicators of maximal effort; e.g., HR_{max} > 90% pred.
 - ◆ normal responses - oxygenation stable or improved, O₂ pulse increases
 - ◆ interpretation
 - poor conditioning - normal pulmonary parameters and O₂ pulse
 - pulmonary disease - low pulmonary parameters
 - cardiac disease - low O₂ pulse

Summary & Review

- ^ **Results may detect:**
 - ◆ measurement error
 - ◆ starvation or ketosis
 - ◆ contributions from carbohydrates, lipids, proteins
 - ◆ underfeeding
 - ◆ overfeeding

References

- ^Ruppel GL. Manual of Pulmonary Function Testing, 9th Ed. Chaps. 5, 7, 9. 2009 Mosby-Elsevier; St. Louis.
- ^Madama VC. Pulmonary function testing and cardiopulmonary stress testing 2nd ed. Chaps. 6, 8, 14, 15. 1998; Delmar; Albany.
- ^Brunelli A, Refai MA, Salati M, Sabbatini A, Morgan-Hughes NJ, Rocco G. Carbon monoxide lung diffusion capacity improves risk stratification in patients without airflow limitation: evidence for systematic measurement before lung resection. *Eur J Cardiothorac Surg.* 2006 Apr;29(4):567-70.
- ^Saydain G, Beck KC, Decker PA, Cowl CT, Scanlon PD. Clinical significance of elevated diffusing capacity. *Chest.* 2004 Feb;125(2):446-52.

References

- ^Price D, Berg J, Lindgren P. An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom. *Allergy.* 2009 Mar;64(3):431-8. Epub 2009 Jan 29.
- ^Rodway GW, Choi J, Hoffman LA, Sethi JM. Exhaled nitric oxide in the diagnosis and management of asthma: clinical implications. *Chron Respir Dis.* 2009;6(1):19-29.
- ^Kwok MY, Walsh-Kelly CM, Gorelick MH. The role of exhaled nitric oxide in evaluation of acute asthma in a pediatric emergency department. *Acad Emerg Med.* 2009 Jan;16(1):21-8. Epub 2008 Nov 27.
- ^Price D, Berg J, Lindgren P. An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom. *Allergy.* 2009 Mar;64(3):431-8. Epub 2009 Jan 29.

References

- ^Bobbio A, Chetta A, Carbognani P, Internullo E, Verduri A, Sansebastiano G, Rusca M, Olivieri D. Changes in pulmonary function test and cardiopulmonary exercise capacity in COPD patients after lobar pulmonary resection. *Eur J Cardiothorac Surg.* 2005 Nov;28(5):754-8.
- ^Lamberto C, Nunes H, Le Toumelin P, Duperron F, Valeyre D, Clerici C. Membrane and capillary blood components of diffusion capacity of the lung for carbon monoxide in pulmonary sarcoidosis: relation to exercise gas exchange. *Chest.* 2004 Jun;125(6):2061-8.
- ^Lee JS, Ra SW, Chae EJ, Seo JB, Lim SY, Kim TH, Lee SD, Oh YM. Validation of the Lower Limit of normal Diffusing Capacity for Detecting Emphysema. *Respiration.* 2010 Jan 29.

References

- ^Kwok MY, Walsh-Kelly CM, Gorelick MH. The role of exhaled nitric oxide in evaluation of acute asthma in a pediatric emergency department. *Acad Emerg Med.* 2009 Jan;16(1):21-8. Epub 2008 Nov 27.
- ^Hewitt RS, Modrich CM, Cowan JO, Herbison GP, Taylor DR. Outcomes using exhaled nitric oxide measurements as an adjunct to primary care asthma management. *Prim Care Respir J.* 2009;18(4):320-7.
- ^Ferguson MK, Gaissert HA, Grab JD, Sheng S. Pulmonary complications after lung resection in the absence of chronic obstructive pulmonary disease: the predictive role of diffusing capacity. *J Thorac Cardiovasc Surg.* 2009 Dec;138(6):1297-302.
- ^Sue DY, Wasserman K. Impact of integrative cardiopulmonary exercise testing on clinical decision making. *Chest.* 1991 Apr;99(4):981-92.

References

- ^Wang JS. Relationship of carbon monoxide pulmonary diffusing capacity to postoperative cardiopulmonary complications in patients undergoing pneumonectomy. *Kaohsiung J Med Sci.* 2003 Sep;19(9):437-46.
- ^Chandra S, Shah SJ, Thenappan T, Archer SL, Rich S, Gomberg-Maitland M. Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. *J Heart Lung Transplant.* 2010 Feb;29(2):181-7. Epub 2009 Sep 26.
- ^Rodway GW, Choi J, Hoffman LA, Sethi JM. Exhaled nitric oxide in the diagnosis and management of asthma: clinical implications. *Chron Respir Dis.* 2009;6(1):19-29.

References

- ^Chetta A, Tzani P, Marangio E, Carbognani P, Bobbio A, Olivieri D. Respiratory effects of surgery and pulmonary function testing in the preoperative evaluation. *Acta Biomed.* 2006 Aug;77(2):69-74.
- ^Milani RV, Lavie CJ, Mehra MR, Ventura HO. Understanding the basics of cardiopulmonary exercise testing. *Mayo Clin Proc.* 2006;81(12):1603-11.
- ^ERS Task Force, Palange P, Ward SA, Carlsen KH, Casaburi R, Gallagher CG, Gosselink R, O'Donnell DE, Puente-Maestu L, Schols AM, Singh S, Whipp BJ. Recommendations on the use of exercise testing in clinical practice. *Eur Respir J.* 2007;29(1):185-209.
- ^Cote CG, Pinto-Plata V, Kasprzyk K, Dordelly LJ, Celli BR. The 6-min walk distance, peak oxygen uptake, and mortality in COPD. *Chest.* 2007;132(6):1778-85.

References

- ^ American Thoracic Society; American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. *Am J Respir Crit Care Med.* 2003 Jan 15;167(2):211-77. Review. Erratum in: *Am J Respir Crit Care Med.* 2003 May 15;1451-2.
- ^ Rasekaba T, Lee AL, Naughton MT, Williams TJ, Holland AE. The six-minute walk test: a useful metric for the cardiopulmonary patient. *Intern Med J.* 2009 Aug;39(8):495-501.
- ^ Benzo RP, Sciruba FC. Oxygen Consumption, Shuttle Walking Test and the Evaluation of Lung Resection. *Respiration.* 2009 Aug 11.
- ^ Benzo RP, Paramesh S, Patel SA, Slivka WA, Sciruba FC. Optimal protocol selection for cardiopulmonary exercise testing in severe COPD. *Chest.* 2007 Nov;132(5):1500-5.

References

- ^ Varela, et al. Measured FEV1 in the first postoperative day, and not ppoFEV1, is the best predictor of cardio-respiratory morbidity after lung resection. *Eur J Cardiothorac Surg* 2007 31: 518-521
- ^ Ferrazza AM, Martolini D, Valli G, Palange P. Cardiopulmonary exercise testing in the functional and prognostic evaluation of patients with pulmonary diseases. *Respiration* 2009;77(1):3-17.
- ^ Pan AM, Stiell IG, Clement CM, Acheson J, Aaron SD. Feasibility of a structured 3-minute walk test as a clinical decision tool for patients presenting to the emergency department with acute dyspnoea. *Emerg Med J.* 2009 Apr;26(4):278-82.
- ^ Buschmann HC, Petermann W. Differential diagnosis of restrictive lung diseases: utility of cardiopulmonary exercise testing. *Pneumologie.* 2010 Jan;64(1):28-36.